From: Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
No. of patients
11
Best overall response (%)
CR
0
(0.0)
PR
2
(18.2)
SD
8
(72.7)
PD
1
(9.1)
ORR
18.2%
DCR
90.9%